bevacizumab + sintilimab

This is a combination therapy consisting of bevacizumab, a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), and sintilimab, a fully human monoclonal antibody that targets programmed cell death protein 1 (PD-1). Bevacizumab acts as an angiogenesis inhibitor by preventing the binding of VEGF to its receptors on the surface of endothelial cells, thereby inhibiting tumor vascularization. Sintilimab is an immune checkpoint inhibitor that restores T-cell antitumor activity by blocking the interaction between PD-1 and its ligands (PD-L1 and PD-L2). The combination is being investigated by Sun Yat-sen University, particularly in the Phase 2 BEST trial, as a treatment for intermediate-stage hepatocellular carcinoma (BCLC stage B) that exceeds the Up-To-Seven criteria, comparing its efficacy and safety against transarterial chemoembolization (TACE).

Brand names

Avastin + Tyvyt

Other names

sintilimab plus bevacizumabsintilimab and bevacizumabBEST trial regimen